Literature DB >> 21378087

The contribution of rapid KATP channel gene mutation analysis to the clinical management of children with congenital hyperinsulinism.

I Banerjee1, M Skae, S E Flanagan, L Rigby, L Patel, M Didi, J Blair, S Ehtisham, S Ellard, K E Cosgrove, M J Dunne, P E Clayton.   

Abstract

OBJECTIVE: In children with congenital hyperinsulinism (CHI), K(ATP) channel genes (ABCC8 and KCNJ11) can be screened rapidly for potential pathogenic mutations. We aimed to assess the contribution of rapid genetic testing to the clinical management of CHI.
DESIGN: Follow-up observational study at two CHI referral hospitals.
METHODS: Clinical outcomes such as subtotal pancreatectomy, (18)F-Dopa positron emission tomography-computed tomography (PET-CT) scanning, stability on medical treatment and remission were assessed in a cohort of 101 children with CHI.
RESULTS: In total, 32 (32%) children had pathogenic mutations in K(ATP) channel genes (27 in ABCC8 and five in KCNJ11), of which 11 (34%) were novel. In those negative at initial screening, other mutations (GLUD1, GCK, and HNF4A) were identified in three children. Those with homozygous/compound heterozygous ABCC8/KCNJ11 mutations were more likely to require a subtotal pancreatectomy CHI (7/10, 70%). Those with paternal heterozygous mutations were investigated with (18)F-Dopa PET-CT scanning and 7/13 (54%) had a focal lesionectomy, whereas four (31%) required subtotal pancreatectomy for diffuse CHI. Those with maternal heterozygous mutations were most likely to achieve remission (5/5, 100%). In 66 with no identified mutation, 43 (65%) achieved remission, 22 (33%) were stable on medical treatment and only one child required a subtotal pancreatectomy.
CONCLUSIONS: Rapid genetic analysis is important in the management pathway of CHI; it provides aetiological confirmation of the diagnosis, indicates the likely need for a subtotal pancreatectomy and identifies those who require (18)F-Dopa PET-CT scanning. In the absence of a mutation, reassurance of a favourable outcome can be given early in the course of CHI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378087     DOI: 10.1530/EJE-10-1136

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  33 in total

Review 1.  Genetic characteristics of patients with congenital hyperinsulinism.

Authors:  Mary Ellen Vajravelu; Diva D De León
Journal:  Curr Opin Pediatr       Date:  2018-08       Impact factor: 2.856

Review 2.  Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis.

Authors:  Giorgio Treglia; Paoletta Mirk; Alessandro Giordano; Vittoria Rufini
Journal:  Pediatr Radiol       Date:  2012-08-12

3.  Next-generation sequencing reveals deep intronic cryptic ABCC8 and HADH splicing founder mutations causing hyperinsulinism by pseudoexon activation.

Authors:  Sarah E Flanagan; Weijia Xie; Richard Caswell; Annet Damhuis; Christine Vianey-Saban; Teoman Akcay; Feyza Darendeliler; Firdevs Bas; Ayla Guven; Zeynep Siklar; Gonul Ocal; Merih Berberoglu; Nuala Murphy; Maureen O'Sullivan; Andrew Green; Peter E Clayton; Indraneel Banerjee; Peter T Clayton; Khalid Hussain; Michael N Weedon; Sian Ellard
Journal:  Am J Hum Genet       Date:  2012-12-27       Impact factor: 11.025

4.  Surgical management of congenital hyperinsulinism in a resource-limited setting.

Authors:  Santosh B Kurbet; Gowda Parameshwar Prashanth; Vijay C Pujar; Manisha R Bhandankar; Sangappa M Dhaded; Mahantesh V Patil
Journal:  J Neonatal Surg       Date:  2013-04-01

5.  Reduced Glycemic Variability in Diazoxide-Responsive Children with Congenital Hyperinsulinism Using Supplemental Omega-3-Polyunsaturated Fatty Acids; A Pilot Trial with MaxEPA(R.).

Authors:  Mars Skae; Hima Bindu Avatapalle; Indraneel Banerjee; Lindsey Rigby; Andy Vail; Peter Foster; Christiana Charalambous; Louise Bowden; Raja Padidela; Leena Patel; Sarah Ehtisham; Karen E Cosgrove; Mark J Dunne; Peter E Clayton
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-12       Impact factor: 5.555

6.  Clinical and Genetic Characteristics, Management and Long-Term Follow-Up of Turkish Patients with Congenital Hyperinsulinism.

Authors:  Ayla Güven; Ayşe Nurcan Cebeci; Sian Ellard; Sarah E Flanagan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12-18

7.  Abnormal Neurodevelopmental Outcomes are Common in Children with Transient Congenital Hyperinsulinism.

Authors:  Hima Bindu Avatapalle; Indraneel Banerjee; Sajni Shah; Megan Pryce; Jacqueline Nicholson; Lindsey Rigby; Louise Caine; Mohammed Didi; Mars Skae; Sarah Ehtisham; Leena Patel; Raja Padidela; Karen E Cosgrove; Mark J Dunne; Peter E Clayton
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-20       Impact factor: 5.555

Review 8.  Congenital hyperinsulinism: current status and future perspectives.

Authors:  Tohru Yorifuji
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-06-30

9.  Enhanced Islet Cell Nucleomegaly Defines Diffuse Congenital Hyperinsulinism in Infancy but Not Other Forms of the Disease.

Authors:  Bing Han; Melanie Newbould; Gauri Batra; Edmund Cheesman; Ross J Craigie; Zainab Mohamed; Lindsey Rigby; Raja Padidela; Mars Skae; Aleksandr Mironov; Tobias Starborg; Karl E Kadler; Karen E Cosgrove; Indraneel Banerjee; Mark J Dunne
Journal:  Am J Clin Pathol       Date:  2016-06       Impact factor: 2.493

10.  Feeding Problems Are Persistent in Children with Severe Congenital Hyperinsulinism.

Authors:  Indraneel Banerjee; Lynette Forsythe; Mars Skae; Hima Bindu Avatapalle; Lindsey Rigby; Louise E Bowden; Ross Craigie; Raja Padidela; Sarah Ehtisham; Leena Patel; Karen E Cosgrove; Mark J Dunne; Peter E Clayton
Journal:  Front Endocrinol (Lausanne)       Date:  2016-02-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.